OvaScience, Inc. (OVAS) Milestone Rewards Option Bulls

OvaScience Inc's (OVAS) Augment fertility treatment produced its first birth

May 7, 2015 at 2:55 PM
facebook twitter linkedin


OvaScience Inc (NASDAQ:OVAS) traders have been buying to open calls at a breakneck pace recently. The fertility stock's 10-day call/put volume ratio across the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) is 8.13. In other words, more than eight OVAS calls have been bought to open for every put over the last two weeks.

Elsewhere on the Street, 100% of analysts tracking the security rate it a "strong buy." What's more, OVAS' consensus 12-month price target of $64 represents a 148.6% premium to the current price of $25.74-- as well as never-before-charted waters.

Today's strong price action is vindicating these optimists. At last check, OVAS shares were 4.8% higher, after the company's Augment fertility treatment produced its first-ever birth. Longer term, though, the picture isn't so rosy. OvaScience Inc (NASDAQ:OVAS) has plunged 41.5% year-to-date.
 

Stop leaving money on the table with the same old broken options trading approach...

There is no options strategy that more perfectly capitalizes during earnings season better than this simple call and put buying strategy. Perfect for aggressive traders looking to recover their suffering portfolios so far in 2022. With the simplest possible options strategy, Schaeffer's team with 100+ years of options trading excellence, target 200% gains on every single trade. So many trades are being beaten down by the market, but don't be one of them! Don't waste another second... join us right now before the next trade is released! 

 
Schaeffer's Daily Bulletin Offer
 


 


 
Special Offers from Schaeffer's Trading Partners